Genetic Testing for Frontotemporal Dementia (FTD)

**Medical Guideline Disclaimer**
Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

**Definitions**
Frontotemporal degeneration (FTD) is a neurodegenerative disease associated with gradual progressive focal atrophy of the frontal and temporal lobes of the brain. FTD caused by heterogenous genetic factors are autosomal dominant and frequently have high penetrance. Common genes that have been implicated are progranulin (PGRN), microtubule-associated-protein-tau (MAPT), and chromosome 9 open reading frame 72 (C9orf72). The clinical presentation of FTD is insidious in onset and variable with language and behavioral disturbances including changes in personality, loss of empathy, poor judgment, alterations in movement, inappropriate social behavior. Visuospatial and memory functions are not affected by the disease. FTD is one of the more common forms of dementia affecting individuals less than age 65 years.

**Related Medical Guideline**
[Genetic Counseling and Testing](#)

**Guideline**
Genetic testing for FTD is considered investigational and not medically necessary for all indications, including:

1. Screening asymptomatic individuals with or without a family history of FTD
2. Diagnosing or predicting the outcome of individuals symptomatic for FTD
3. Prenatal or preimplantation genetic testing to diagnosis FTD in the offspring when a genetic mutation known to caused FTD has been identified in the parent

**Applicable Procedure Codes**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>81406</td>
<td>Molecular pathology procedure, Level 7 (e.g., analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia) ANOS1 (anosmin-1) (eg, Kallmann syndrome 1), full gene sequence HMBS (hydroxymethylbilane synthase) (eg, acute intermittent porphyria), full gene sequence PPOX (protoporphyrinogen oxidase) (eg, variegate porphyria), full gene sequence (Revision eff. 01/01/2018)</td>
</tr>
<tr>
<td>81479</td>
<td>Unlisted molecular pathology procedure</td>
</tr>
</tbody>
</table>
References


